753 related articles for article (PubMed ID: 17561264)
1. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology.
Brinkmann V
Pharmacol Ther; 2007 Jul; 115(1):84-105. PubMed ID: 17561264
[TBL] [Abstract][Full Text] [Related]
2. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.
Dev KK; Mullershausen F; Mattes H; Kuhn RR; Bilbe G; Hoyer D; Mir A
Pharmacol Ther; 2008 Jan; 117(1):77-93. PubMed ID: 17961662
[TBL] [Abstract][Full Text] [Related]
3. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
Mehling M; Johnson TA; Antel J; Kappos L; Bar-Or A
Neurology; 2011 Feb; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
[TBL] [Abstract][Full Text] [Related]
4. Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis.
Lee CW; Choi JW; Chun J
Arch Pharm Res; 2010 Oct; 33(10):1567-74. PubMed ID: 21052934
[TBL] [Abstract][Full Text] [Related]
5. Sphingosine-1-phosphate and FTY720 as anti-atherosclerotic lipid compounds.
Tölle M; Levkau B; Kleuser B; van der Giet M
Eur J Clin Invest; 2007 Mar; 37(3):171-9. PubMed ID: 17359484
[TBL] [Abstract][Full Text] [Related]
6. FTY720 modulates human oligodendrocyte progenitor process extension and survival.
Miron VE; Jung CG; Kim HJ; Kennedy TE; Soliven B; Antel JP
Ann Neurol; 2008 Jan; 63(1):61-71. PubMed ID: 17918267
[TBL] [Abstract][Full Text] [Related]
7. The role of the lysophospholipid sphingosine 1-phosphate in immune cell biology.
von Wenckstern H; Zimmermann K; Kleuser B
Arch Immunol Ther Exp (Warsz); 2006; 54(4):239-51. PubMed ID: 16830220
[TBL] [Abstract][Full Text] [Related]
8. Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.
Chiba K; Adachi K
Future Med Chem; 2012 Apr; 4(6):771-81. PubMed ID: 22530640
[TBL] [Abstract][Full Text] [Related]
9. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors.
Chiba K
Pharmacol Ther; 2005 Dec; 108(3):308-19. PubMed ID: 15951022
[TBL] [Abstract][Full Text] [Related]
10. Fingolimod for relapsing multiple sclerosis: an update.
Horga A; Castilló J; Montalban X
Expert Opin Pharmacother; 2010 May; 11(7):1183-96. PubMed ID: 20367536
[TBL] [Abstract][Full Text] [Related]
11. [Therapeutic effect of S1P receptor modifying drugs for autoimmune diseases].
Chiba K; Kataoka H
Nihon Yakurigaku Zasshi; 2008 Mar; 131(3):24-5. PubMed ID: 18421849
[No Abstract] [Full Text] [Related]
12. Synthesis of 4(5)-phenylimidazole-based analogues of sphingosine-1-phosphate and FTY720: discovery of potent S1P1 receptor agonists.
Clemens JJ; Davis MD; Lynch KR; Macdonald TL
Bioorg Med Chem Lett; 2005 Aug; 15(15):3568-72. PubMed ID: 15982878
[TBL] [Abstract][Full Text] [Related]
13. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.
Brinkmann V
Br J Pharmacol; 2009 Nov; 158(5):1173-82. PubMed ID: 19814729
[TBL] [Abstract][Full Text] [Related]
14. [Research progress of the selective sphingosine-1-phosphate receptor 1 agonists].
Tian YL; Jin J; Wang XJ
Yao Xue Xue Bao; 2012 Jan; 47(1):7-17. PubMed ID: 22493799
[TBL] [Abstract][Full Text] [Related]
15. Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions.
Van Doorn R; Van Horssen J; Verzijl D; Witte M; Ronken E; Van Het Hof B; Lakeman K; Dijkstra CD; Van Der Valk P; Reijerkerk A; Alewijnse AE; Peters SL; De Vries HE
Glia; 2010 Sep; 58(12):1465-76. PubMed ID: 20648639
[TBL] [Abstract][Full Text] [Related]
16. Cis-4-methylsphingosine is a sphingosine-1-phosphate receptor modulator.
Ter Braak M; Claas RF; Hegen B; Labocha S; Ferreirós N; Pfeilschifter J; Huwiler A; van Echten-Deckert G; Meyer Zu Heringdorf D
Biochem Pharmacol; 2011 Mar; 81(5):617-25. PubMed ID: 21163254
[TBL] [Abstract][Full Text] [Related]
17. Central nervous system-directed effects of FTY720 (fingolimod).
Miron VE; Schubart A; Antel JP
J Neurol Sci; 2008 Nov; 274(1-2):13-7. PubMed ID: 18678377
[TBL] [Abstract][Full Text] [Related]
18. Impact of sphingosine 1-phosphate modulation on immune outcomes.
Pinschewer DD; Brinkmann V; Merkler D
Neurology; 2011 Feb; 76(8 Suppl 3):S15-9. PubMed ID: 21339486
[TBL] [Abstract][Full Text] [Related]
19. FTY720 inhibits S1P-mediated endothelial healing: relationship to S1P1-receptor surface expression.
Krump-Konvalinkova V; Chwalla I; Siess W
Biochem Biophys Res Commun; 2008 Jun; 370(4):603-8. PubMed ID: 18402775
[TBL] [Abstract][Full Text] [Related]
20. Phosphorylated FTY720 stimulates ERK phosphorylation in astrocytes via S1P receptors.
Osinde M; Mullershausen F; Dev KK
Neuropharmacology; 2007 Apr; 52(5):1210-8. PubMed ID: 17379261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
